QuidelOrtho: Q3 Earnings Snapshot

QuidelOrtho (QDEL) reported a Q3 loss of $53.8M, or 78 cents per share, with adjusted earnings of 31 cents per share. Revenue was $618.9M. The company expects full-year earnings of 65-70 cents per share and revenue of $2.52B-$2.54B, according to its Tuesday report.

Original reporting
Published Nov 3, 2026, 9:17 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 9:25 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
QuidelOrtho: Q3 Earnings Snapshot — source image
Decision brief

The 30-second read

$QDELBearishHigh
01

Why it matters

The earnings miss may trigger short‑term sell‑offs, but the revenue guidance suggests a stable top line.

02

Market read

First‑report earnings release with new loss figures and guidance, directly affecting QDEL's price.

03

What to watch

Potential upcoming product launches or contract wins not disclosed in this release could offset short‑term weakness.

Relevance 8/10Novelty 8/10Timing: post‑market today

Background

QuidelOrtho is a medical diagnostics company that provides rapid testing solutions.

Company-level read

Ticker impact

$QDELBearishHigh confidence
Context

QDEL reported a Q3 loss of $53.8M, revenue of $618.9M and gave FY guidance of $2.52‑$2.54B.

Expected impact

downward pressure as investors price in the loss and lower outlook

Evidence & confidence

The company posted a loss and narrowed guidance, which historically triggers sell‑offs.

Market effects

Diagnostic testing sector may see modest pullback as earnings miss signals demand pressure.

US healthcare stocks could face slight downside in after‑hours trading.

Limited; impact confined to US biotech/diagnostics investors.

Counterpoint

If the loss is viewed as a temporary setback and the FY revenue range remains strong, the stock could be a buying opportunity.

Key entities

  • QuidelOrtho Corporation

    US‑listed diagnostics firm (NASDAQ: QDEL).

Related articles

$QDELMedAI 8/10

QuidelOrtho (QDEL) Q3 2026 Earnings Call Transcript

QuidelOrtho reported Q3 2026 revenue of $619M, down 12% YoY, with declines in Point of Care and China sales. Excluding China and respiratory, revenue rose 3%. The company announced a restructuring program to save $80M annually in 2027, focusing on cost cuts and business realignment. Management emphasized long-term growth strategies, including expanding the VITROS 450 and NULEXA platforms.

$QDELHighAI 8/10

QuidelOrtho Corp (QDEL) Q3 2026 Earnings Call Highlights: Revenue Falls 12% on China

QuidelOrtho Corp (QDEL) reported a 12% year-over-year revenue decline to $619 million in Q3 2026, driven by China destocking and softer respiratory testing. China revenue dropped 45% due to pricing changes and destocking, with further pressure expected. Adjusted gross margin contracted to 47.8%, and net leverage increased to 4.5 times EBITDA. The company plans cost savings and structural changes to offset headwinds and improve profitability.

$QDELMedAI 8/10

What QuidelOrtho (QDEL) Said on Its Q3 Earnings Call

QuidelOrtho (QDEL) reported Q3 revenue decline, with Point of Care down 27% YoY. Management maintained a cautious outlook. The company announced a restructuring program targeting $80M in annual savings by 2027, with $30M-$35M in one-time charges in Q4. Adjusted EBITDA was $148M, and adjusted EPS was $0.31. QDEL narrowed its full-year revenue outlook to $2.52B-$2.54B and adjusted EBITDA to $540M-$545M.

$QDELHighAI 8/10

QuidelOrtho Q3 2026 slides: profit beat masks revenue challenges

QuidelOrtho (QDEL) reported Q3 2026 earnings of $0.31 per share, beating estimates, but revenue of $618.9M missed forecasts, causing a 6.62% after-hours drop. Revenue declined 12% YoY due to China's IVD pricing guidelines, with North America down 13.3% and China down 45.5%. Management narrowed full-year guidance, citing continued China pressure and cautious respiratory demand outlook. The company announced a restructuring plan to save $80M annually from 2027.